Prof Dr Tanja D. de Gruijl
Tanja D. de Gruijl heads the Immunotherapy and Immune monitoring Lab at the Cancer Center of the Amsterdam university medical centers, where she has been appointed Professor of Translational Tumour Immunology and holds a Fenna Diemer Lindeboom Chair. Her research ranges from preclinical topics to immune monitoring of Phase I-III clinical trials and includes topics like the immune potentiation of tumour-draining lymph nodes and the tumour microenvironment, immunological arming of oncolytic adenoviruses, and nanobody-mediated targeting of (NK)T-cell subsets. Tanja has supervised the research that supported the foundation of DCprime and is co-founder of LAVA Therapeutics. She has recently been elected on the board of directors of the Society for the Immunotherapy of Cancer (SITC).